Renal transplant allocation criteria, desensitization strategies and immunosuppressive therapy in retransplant renal patients

Journal of Nephrology

Volumn 25, Issue 6, 2012, Pages 890-899

  Salvadori, Maurizio ^a   Bertoni, Elisabetta ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Immunosuppression; Kidney allocation criteria; Kidney retransplantation; Sensitization

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BORTEZOMIB; ECULIZUMAB; HLA A ANTIGEN; HLA ANTIBODY; HLA B ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SCREENING; DESENSITIZATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG MEGADOSE; GRAFT SURVIVAL; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRACTICE GUIDELINE; PROGRAM DEVELOPMENT; REOPERATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

DONOR SELECTION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; PREDICTIVE VALUE OF TESTS; REOPERATION; RISK ASSESSMENT; RISK FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84870582202     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000207     Document Type: Review

References (87)

1. Organ Procurement and Transplantation Network/US Scientific Registry of Transplant Recipients. 2010 OPTN/SRTR annual report. Available at: http://optn.transplant.hrsa.gov/. Accessed July 18, 2012.
2. Collaborative Transplant Study [website home page]. Available at: http://www.ctstransplant.org/. Accessed March 2012.
3. Rao PS, Schaubel DE, Wei G, Fenton SS. Evaluating the survival benefit of kidney retransplantation. Transplantation. 2006;82(5):669-674.
4. Ojo A, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation. 1998;66(12): 1651-1659.
5. Sellers MT, Velidedeoglu E, Bloom RD, et al. Expandedcriteria donor kidneys: a single-center clinical and short-term financial analysis: cause for concern in retransplantation. Transplantation. 2004;78(11):1670-1675.
6. El-Agroudy AE, Wafa EW, Bakr MA, et al. Living-donor kidney retransplantation: risk factors and outcome. BJU Int. 2004;94(3):369-373.
7. Abouljoud MS, Deierhoi MH, Hudson SL, Diethelm AG. Risk factors affecting second renal transplant outcome, with special reference to primary allograft nephrectomy. Transplantation. 1995;60(2):138-144.
8. Arnol M, Prather JC, Mittalhenkle A, Barry JM, Norman DJ. Long-term kidney regraft survival from deceased donors: risk factors and outcomes in a single center. Transplantation. 2008;86(8):1084-1089.
9. Gjertson DW. A multi-factor analysis of kidney regraft outcomes. Clin Transpl. 2002;335-349.
10. Miles CD, Schaubel DE, Jia X, Ojo AO, Port FK, Rao PS. Mortality experience in recipients undergoing repeat transplantation with expanded criteria donor and non-ECD deceased-donor kidneys. Am J Transplant. 2007;7(5):1140-1147.
11. Scornik JC. Detection of alloantibodies by flow cytometry: relevance to clinical transplantation. Cytometry. 1995; 22(4):259-263.
12. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2007 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; section e_5: 26-27. Available at: http://www.srtr.org. Accessed August 2012.
13. European Association of Urology. Guidelines on renal transplantation of the European Association of Urology 2010. Available at: http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Renal_Transplant.pdf
14. United Kingdom Guidelines for Living Donor Kidney Transplantation. Compiled by a joint working party of the British Transplantation Society and the Renal Association. Burnapp L, Lear P, Baboolal K, et al. Posted on: www.bts.org.uk and www.renal.org. Accessed November 2011.
15. Ponticelli C. The mechanisms of acute transplant rejection revisited. J Nephrol. 2012;25(2):150-158.
16. Opelz G, Terasaki PI. Recipient selection for renal retransplantation. Transplantation. 1976;21(6):483-488.
17. Claas FH, Doxiadis II. Management of the highly sensitized patient. Curr Opin Immunol. 2009;21(5):569-572.
18. Martin S, Claas F. Antibodies and crossmatching for transplantation. In: Dyer PA, Middleton D, eds. Histocompatibility testing: a practical approach. Oxford: IRL Press; 1993: 97-105.
19. Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates PT. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol. 2009;70(8):595-599.
20. Fuggle SV, Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation. 2008;86(3):384-390.
21. Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibodymediated rejection and deceased-donor kidney allograft survival. Hum Immunol. 2009;70(8):589-594.
22. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant. 2007;7(4):1027-1031.
23. Schwartz A, Gaigalas AK, Wang L, Marti GE, Vogt RF, Fernandez-Repollet E. Formalization of the MESF unit of fluorescence intensity. Cytometry B Clin Cytom. 2004;57(1): 1-6.
24. Gupta A, Sinnott P. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum Immunol. 2009;70(8):618-622.
25. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation. 2008;85(8):1200-1204.
26. Riethmüller S, Ferrari-Lacraz S, Müller MK, et al. Donorspecific antibody levels and three generations of cross matches to predict antibody-mediated rejection in kidney transplantation. Transplantation. 2010;90(2):160-167.
27. Gebel HM, Moussa O, Eckels DD, Bray RA. Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums. Hum Immunol. 2009; 70(8):610-617.
28. Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donorspecific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol. 2009;70(8):584-588.
29. van den Berg-Loonen EM, Billen EVA, Voorter CEM, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation. 2008;85(8):1086-1090.
30. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4(7):1033-1041.
31. Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol. 2009;70(8):563-568.
32. Meier-Kriesche HU, Scornik JC, Susskind B, Rehman S, Schold JD. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation. 2009;88(1):23-29.
33. Scornik JC, Kriesche HU. Human leukocyte antigen sensitization after transplant loss: timing of antibody detection and implications for prevention. Hum Immunol. 2011;72(5): 398-401.
34. Dawson KL, Patel SJ, Xu J, Knight RJ, Gaber AO. Effect of immunosuppression for first kidney or kidney/pancreas transplant on sensitization at the time of second transplant. Transplantation. 2011;91(7):751-756.
35. Del Bello A, Congy N, Sallusto F, et al. Anti-human leukocyte antigen immunization after early allograft nephrectomy. Transplantation. 2012;93(9):936-941.
36. Budde K, Dürr M. About incidence and timing of donorspecific antibodies after graft nephrectomy. Transplantation. 2012;93(9):865-866.
37. Lenaers J, Christiaans M, van Heurn E, van Hooff H, van den Berg-Loonen E. Frequent but late donor-directed antibody formation after kidney transplantectomy within one month after grafting. Transplantation. 2006;81(4):614-619.
38. Johnston O, Rose C, Landsberg D, Gourlay WA, Gill JS. Nephrectomy after transplant failure: current practice and outcomes. Am J Transplant. 2007;7(8):1961-1967.
39. Ahmad N, Ahmed K, Mamode N. Does nephrectomy of failed allograft influence graft survival after re-transplantation? Nephrol Dial Transplant. 2009;24(2):639-642.
40. Schleicher C, Wolters H, Kebschull L, et al. Impact of failed allograft nephrectomy on initial function and graft survival after kidney retransplantation. Transpl Int. 2011;24(3):284-291.
41. Cecka JM, Terasaki PI. Repeating HLA antigen mismatches in renal retransplants: a second class mistake? Transplantation. 1994;57(4):515-519.
42. Mjörnstedt L, Konar J, Nyberg G, Olausson M, Sandberg L, Karlberg I. Renal retransplantation in patients with HLA-antibodies. Transpl Int. 1992;5(Suppl 1):S32-S34.
43. House AA, Chang PCW, Luke PP, et al. Re-exposure to mismatched HLA class I is a significant risk factor for graft loss: multivariable analysis of 259 kidney retransplants. Transplantation. 2007;84(6):722-728.
44. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12(5):1157-1167.
45. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor specific HLA antibodies after kidney transplantation. J Am Soc Nephrol. 2005;16(9):2804-2812.
46. Doxiadis II, Witvliet MD, Verduyn W, et al. The relevance of proficiency testing for laboratories involved in cadaveric organ transplantation and its consequences for graft survival. Clin Transpl. 2000;99-103.
47. Duquesnoy RJ. Clinical usefulness of HLA Matchmaker in HLA epitope matching for organ transplantation. Curr Opin Immunol. 2008;20(5):594-601.
48. Duquesnoy RJ, Witvliet M, Doxiadis II, de Fijter H, Claas FH. HLA Matchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates. Transpl Int. 2004;17(1):22-30.
49. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation. 2009;88(4):447-452.
50. de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Claas FH, Weimar W. Hurdles, barriers, and successes of a national living donor kidney exchange program. Transplantation. 2008;86(12):1749-1753.
51. Segev DL, Kucirka LM, Gentry SE, Montgomery RA. Utilization and outcomes of kidney paired donation in the United States. Transplantation. 2008;86(4):502-510.
52. Hanto RL, Reitsma W, Delmonico FL. The development of a successful multiregional kidney paired donation program. Transplantation. 2008;86(12):1744-1748.
53. Rees MA, Kopke JE, Pelletier RP, et al. A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med. 2009; 360(11):1096-1101.
54. Bingaman AW, Wright FH, Murphey CL. Kidney paired donation in live-donor kidney transplantation. N Engl J Med. 2010;363(11):1091-1092.
55. Connolly JS, Terasaki PI, Veale JL. Kidney paired donation: the next step. N Engl J Med. 2011;365(9):868-869.
56. Magee C, Clarkson M, Rennke H. A case of desensitization, transplantation, and allograft dysfunction. Clin J Am Soc Nephrol. 2008;3(5):1573-1581.
57. Barocci S, Valente U, Fontana I, et al. Long-term outcome on kidney retransplantation: a review of 100 cases from a single center. Transplant Proc. 2009;41(4):1156-1158.
58. Soran A, Basar H, Shapiro R, et al. Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. Transplant Proc. 2000;32(3):663-664.
59. Noël C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol. 2009;20(6): 1385-1392.
60. Gurk-Turner C, Airee R, Philosophe B, Kukuruga D, Drachenberg C, Haririan A. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation. 2008;85(10):1425-1430.
61. Cai J, Terasaki PI. Current trend of induction and maintenance treatment in positive panel-reactive antibody patients: a report on OPTN/UNOS kidney transplant registry data. Chin Med J (Engl). 2011;124(5):649-654.
62. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;2(8):758-760.
63. Morath C, Beimler J, Opelz G, et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation. 2010;90(6):645-653.
64. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donorspecific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398-1406.
65. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol. 2011;6(4):922-936.
66. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998;66(6):800-805.
67. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003;76(4):631-636.
68. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242-251.
69. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15(12):3256-3262.
70. Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol. 2006;1(3):421-432.
71. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donorspecific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation. 2008;86(6):820-825.
72. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89(9):1095-1102.
73. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant. 2010;10(9):2033-2042.
74. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant. 2004;8(6):535-542.
75. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365(4):318-326.
76. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6(2):346-351.
77. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet. 1996;348(9036): 1208-1211.
78. Haas M, Böhmig GA, Leko-Mohr Z, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant. 2002;17(8):1503-1508.
79. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation. 2010;89(11):1403-1410.
80. Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: the University of Wisconsin initial experience. Transplantation. 2011;92(1):12-17.
81. Gloor J, Stegall MD. Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol. 2010;6(5):297-306.
82. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754-1761.
83. Everly MJ, Terasaki PI, Trivedi HL. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation. 2012;93(6):572-577.
84. Everly MJ, Everly JJ, Terasaki PI. Role of proteasome inhibition in sensitized transplant candidates. Chin Med J (Engl). 2011;124(5):771-774.
85. Kute VB, Vanikar AV, Trivedi HL, et al. Desensitization protocol for highly sensitized renal transplant patients: a singlecenter experience. Saudi J Kidney Dis Transpl. 2011;22(4): 662-669.
86. Guthoff M, Schmid-Horch B, Weisel KC, Häring HU, Königsrainer A, Heyne N. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol. 2012;26(4):171-175.
87. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011; 11(11):2405-2413.